Hosted on MSN
Nexalin launches pivotal HALO Clarity trial to support FDA submission for insomnia treatment
Nexalin Technology, Inc. (NASDAQ:NXL) has initiated its pivotal HALO Clarity clinical trial, a key step toward a planned de novo submission to the U.S. Food and Drug Administration seeking clearance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results